izumenolide: from Micromonospora chalcea [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6441868 |
| MeSH ID | M0097141 |
| Synonym |
|---|
| oxacyclotriacont-3-en-2-one, 16,18-bis(sulfooxy)-30-(2-(sulfooxy)-9-undecenyl)- |
| em-4615-a |
| izumenolide |
| [(e)-1-[(28e)-30-oxo-14,16-disulfooxy-1-oxacyclotriacont-28-en-2-yl]undec-9-en-2-yl] hydrogen sulfate |
| 76265-39-9 |
Izumenolide is a macrolide containing sulfate ester groups. It is an inhibitor of beta-lactamases, especially from Gram-negative bacteria.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Izumenolide is a macrolide containing sulfate ester groups." | ( Izumenolide-a novel beta-lactamase inhibitor produced by Micromonospora. I. Detection, isolation and characterization. Astle, G; Kocy, OR; Liu, WC; Parker, WL; Principe, PA; Rathnum, ML; Sykes, RB; Trejo, WH; Wells, JS, 1980) | 2.43 |
| "Izumenolide is a potent inhibitor of beta-lactamases, especially from Gram-negative bacteria. " | ( Izumenolide-a novel beta-lactamase inhibitor produced by Micromonospora. II. Biological properties. Bonner, DP; Bush, K; Sykes, RB, 1980) | 3.15 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||